Global Research

Vertex to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 20, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:
    TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 a.m.
  • Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 4:00 p.m.
  • A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.
  • A replay of the conference webcast will be archived on the company's website.

Alliance One Positions Business for Growth in International Seed Sector

Retrieved on: 
Thursday, January 18, 2024

MORRISVILLE, N.C., Jan. 18, 2024 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce the recent opening of its seed industrialization unit, the latest investment in its Global Research, Development and Deployment Center in Passo do Sobrado, Brazil.

Key Points: 
  • MORRISVILLE, N.C., Jan. 18, 2024 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce the recent opening of its seed industrialization unit, the latest investment in its Global Research, Development and Deployment Center in Passo do Sobrado, Brazil.
  • Alliance One is the leading supplier in Brazil's tobacco seed market, with tobacco grown from the Company's varieties comprising approximately 40 percent of the tobacco produced in the country.
  • The installation of its new, state-of-the-art seed industrialization unit positions the Company for global growth as a leader in tobacco crop solutions with the ability to provide customers and farmers with best-in-class genetics.
  • "Improved quality control opens doors to sell our seed in new markets at a faster speed, increases customer and farmer satisfaction, and drives efficiencies within our business."

Kaspersky survey: 71% of drivers would buy a car with less tech to protect their privacy

Retrieved on: 
Thursday, January 11, 2024

WOBURN, Mass., Jan. 11, 2024 /PRNewswire/ -- Kaspersky has released a new survey report showing that 72 percent of drivers are uncomfortable with the idea of automakers sharing their data with third parties. The report, "Is my car spying on me?" captures drivers' thoughts about automakers' use of personal data gleaned from connected cars. Eighty-seven percent of survey participants said automakers should be required to delete their data upon request, and only 28% said they have some idea what kind of data their car collects.

Key Points: 
  • Some car manufacturers are even setting up subscription services , based on in-car tech features, to create new, multi-billion dollar lines of revenue.
  • To find out more about drivers' level of awareness and concern about these issues, Kaspersky surveyed 2,000 U.S. drivers in November 2023.
  • Strikingly, 71% of drivers even said they would consider buying an older car or one with less technology, in order to protect their privacy and security.
  • Buy an older car or a car with a minimal set of "smart" sensors and/or no communication module.

ConcertAI and Caris Life Sciences Announce Strategic Agreement with AbbVie to Accelerate Oncology Pipeline and Clinical Trials

Retrieved on: 
Tuesday, January 9, 2024

CAMBRIDGE, Ma. and IRVING, Texas, Jan. 9, 2024 /PRNewswire/ -- ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and clinical trial optimization in oncology.

Key Points: 
  • Agreement enables AbbVie to leverage ConcertAI and Caris' extensive clinical and genomic databases, coupled with Artificial Intelligence and Machine Learning (AI/ML)-derived insights to accelerate drug discovery, clinical development and precision medicine efforts in oncology
    CAMBRIDGE, Ma.
  • and IRVING, Texas, Jan. 9, 2024 /PRNewswire/ -- ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and clinical trial optimization in oncology.
  • The agreement will also allow AbbVie to utilize ConcertAI and Caris' clinical network and laboratory capabilities combined with AI/ ML learning to optimize oncology clinical trials and patient enrollment.
  • "This work may help identify novel targets and mechanisms, and key levers to drive clinical trial excellence to support AbbVie's oncology portfolio."

Barclays appoints Ryan Voegeli as Head of Investment Banking for Canada

Retrieved on: 
Thursday, January 4, 2024

Barclays today announces the appointment of Ryan Voegeli as Head of Investment Banking for Canada.

Key Points: 
  • Barclays today announces the appointment of Ryan Voegeli as Head of Investment Banking for Canada.
  • Mr. Voegeli has twenty years of investment banking experience, and joins Barclays from CIBC Capital Markets where he was Head of Global Diversified Industries Investment Banking.
  • Prior to joining CIBC in 2011, Mr. Voegeli was Head of Canadian Telecom, Media & Technology Investment Banking at Bank of America Merrill Lynch.
  • The Barclays Canada team delivers Investment Banking, Global Markets, and Global Research coverage, providing clients in Canada with seamless access to Barclays’ global network, and extensive in-country opportunities for international clients.

Vertex to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, October 26, 2023

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
  • Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in a fireside chat at UBS Biopharma Conference on Thursday, November 9, 2023 at 12:00 p.m.
  • Stuart Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 8:30 a.m. GMT.
  • A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.

Barclays appoints Geoffrey Belsher as Chairman and Country Chief Executive Officer for Canada

Retrieved on: 
Friday, October 13, 2023

Barclays today announces the appointment of Geoffrey Belsher as Chairman and Country Chief Executive Officer for Canada, effective Monday 16 October and subject to regulatory approval.

Key Points: 
  • Barclays today announces the appointment of Geoffrey Belsher as Chairman and Country Chief Executive Officer for Canada, effective Monday 16 October and subject to regulatory approval.
  • As Chairman and Country CEO, he will be a local leader for Barclays in Canada, responsible for executing the country strategy in line with the bank’s regional and global ambitions.
  • “Barclays has a long and storied history in Canada,” says Mr. Belsher.
  • “I’m incredibly proud to join this team and look forward to this new opportunity at Barclays.”

Dotmatics Releases New Chemicals & Materials Solution Focused on Data-Driven Research to Accelerate Product Development

Retrieved on: 
Wednesday, September 27, 2023

BOSTON, Sept. 27, 2023 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced its new Dotmatics Chemicals & Materials Solution specifically designed to help R&D leaders get more insight from their data, faster. With its focus on simplifying data intelligence, the new Dotmatics Chemicals & Materials Solution helps researchers accelerate new product development by enabling data-driven research, simplifying project management, and reducing the complexities of research IT infrastructure. Learn more at: https://www.dotmatics.com/solutions/chemicals-materials-science-software.

Key Points: 
  • With its focus on simplifying data intelligence, the new Dotmatics Chemicals & Materials Solution helps researchers accelerate new product development by enabling data-driven research, simplifying project management, and reducing the complexities of research IT infrastructure.
  • "We are bringing the Dotmatics Chemicals & Materials solution to market specifically to empower teams to gain insights, make informed decisions, and streamline workflows, ultimately driving greater efficiency and productivity."
  • The Dotmatics Chemicals & Materials Solution includes the following workflows and capabilities:
    Ingredient Management: Leverages Dotmatics Bioregister as a general entity registration framework to define and track ingredient properties.
  • The Dotmatics Chemicals & Materials Solution is now generally available to help researchers accelerate new product development.

Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences

Retrieved on: 
Thursday, September 14, 2023

“The research teams led by Paul, Fred and Sabine discovered the first and only medicines that address the underlying cause of cystic fibrosis.

Key Points: 
  • “The research teams led by Paul, Fred and Sabine discovered the first and only medicines that address the underlying cause of cystic fibrosis.
  • Vertex is currently developing a next-in-class investigational CF triple combination therapy, now in Phase 3 trials, that has the potential for enhanced clinical benefit.
  • The Breakthrough Prize in Life Sciences was founded in 2013 by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Yuri and Julia Milner, and Anne Wojcicki.
  • Breakthrough Prizes are also awarded annually in the fields of Fundamental Physics and Mathematics.

EQS-News: Biotest AG: Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

Retrieved on: 
Monday, September 4, 2023

The Supervisory Board of Biotest AG extended the Management Board contract of Dr Jörg Schüttrumpf (49) by 5 years until 31 August 2028.

Key Points: 
  • The Supervisory Board of Biotest AG extended the Management Board contract of Dr Jörg Schüttrumpf (49) by 5 years until 31 August 2028.
  • This is in recognition of his many years of successful work as Head of Research and Development and, since the beginning of 2022, as Chief Scientific Officer (CSO) on the Management Board of Biotest AG.
  • Dr Schüttrumpf has been Head of Global Research at Biotest AG since 2012 and Head of Research and Development since 2015.
  • In addition, the Spanish parent company of Biotest AG, Grifols S.A., has asked Dr Schüttrumpf to assume the role of 'Chief Scientific Innovation Officer' for the entire Grifols Group.